Skip to main content
. 2017 Nov 30;9:741–750. doi: 10.2147/CMAR.S146897

Figure 4.

Figure 4

Comparison of recurrence-free survival rates between patients with high CD8-positive TILs counts versus those with low CD8-positive TILs counts (A), high PD-L1 expressions versus low PD-L1 expressions (B), and tumor microenvironment type IV versus type I versus type II versus type III (C). P=0.038, 0.006, and 0.002, respectively.

Abbreviations: CD8-positive TILs, tumor-infiltrating CD8-positive T lymphocytes; PD-L1, programmed cell death-1 ligand 1.